DAIC

JULY 18, 2024

HeartFlow’s Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. F.A.C.C. “The

Coronary Artery Disease 111

Coronary Artery Disease Plaque Technology Medicare 111

DAIC

MARCH 27, 2025

In 2024, the FDA approved Flyrcado for patients with known or suspected coronary artery disease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.

Coronary Artery Disease 52

Coronary Artery Disease CMS Innovation Ischemia 52

DAIC

JUNE 18, 2024

Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. After implantation, the locked phase establishes the maximum flow lumen and restores blood flow to treat symptoms of coronary artery disease (CAD).

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

DAIC

OCTOBER 16, 2024

15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). tim.hodson Wed, 10/16/2024 - 12:36 Oct. The four contractors for the U.S. The LCDs have a future effective date of Nov.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

MARCH 20, 2024

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6% Jörg Pochert, President of Vascular Intervention at Biotronik.

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease 105

DAIC

JANUARY 3, 2024

With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes. 3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives.

Coronary Artery Disease 59

Coronary Artery Disease Chest Pain Plaque Technology 59

Wellnest

JUNE 19, 2023

The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patient care. What is Artificial Intelligence?

Technology 52

Technology Cardiac Arrest Innovation Coronary Artery Disease 52